Filing Analysis
Tredegar Corporation filed an 8-K to announce its third quarter 2024 financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the earnings release furnished via Exhibit 99.
📋 Key Facts
- Report date: November 08, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing contains results of operations and financial condition under Item 2.02.
- Financial statements were furnished as Exhibit 99 via a press release.
Tredegar Corporation has completed the sale of 100% of its flexible packaging films business (Terphane LLC and Terphane Limitada) to Oben US, LLC and Film Trading Importação e Representação Ltda. for a total consideration of $116 million.
🚩 Red Flags
- Divestiture of a significant business segment (flexible packaging films) may change the company's risk profile or growth trajectory.
- Transition services agreement indicates ongoing operational dependency on Tredegar for the divested entity's continuity.
📋 Key Facts
- Transaction completed on November 1, 2024 (accounting effective date October 31, 2024).
- Aggregate purchase price: $116 million.
- The divestiture includes Terphane LLC and Terphane Limitada.
- Tredegar will provide transition services (payroll, finance, tax, and IT) to the buyers via a transition services agreement.
- Unaudited pro forma financial information has been provided for various periods ending June 30, 2024, and fiscal years 2023, 2022, and 2021.
Tredegar Corporation announced that Brazil's competition authority (CADE) has approved the sale of its Terphane flexible packaging films business to Oben Group. The transaction is expected to close on November 1, 2024.
📋 Key Facts
- Brazilian Administrative Council for Economic Defense (CADE) granted merger control approval.
- The sale involves the 'Terphane' flexible packaging films business.
- Buyer is Oben Group.
- Transaction closing is expected on November 1, 2024.
- Approval was contingent upon post-closing commitments by Oben Group to address competition concerns.
Tredegar Corporation has filed an 8-K to announce its second quarter 2024 financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reporting date: August 07, 2024
- Period covered: Second Quarter ended June 30, 2024
- The filing includes results of operations and financial condition as per Item 2.02.
- Financial statements are furnished via Exhibit 99 (Press Release).
Tredegar Corporation reported a setback in the regulatory approval process for its sale of the Terphane business to Oben Group. The Brazilian antitrust authority (SG-CADE) issued a non-binding opinion recommending the rejection of the transaction, moving the case to the CADE Tribunal for further review.
🚩 Red Flags
- Regulatory hurdle: Non-binding recommendation from Brazilian antitrust authorities (SG-CADE) to reject the divestiture.
📋 Key Facts
- The sale of the flexible packaging films ('Terphane') business is to Oben Group.
- On May 13, 2024, SG-CADE issued a non-binding opinion recommending rejection of the transaction.
- The case will now proceed to the CADE Tribunal for an independent analysis and final decision.
- The maximum deadline for CADE's final decision is November 18, 2024.
Tredegar Corporation held its Annual Meeting of Shareholders on May 9, 2024. The filing reports the election of six directors and the ratification of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting of Shareholders held on May 9, 2024.
- Quorum was present with 30,029,166 shares represented in person or by proxy.
- All six director nominees (Freeman, Newsome, Pratt, Snead, Steitz, and Tack) were elected.
- Advisory vote on executive compensation (Say-on-Pay) was approved on a non-binding basis with 16,178,738 votes in favor.
- Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Tredegar Corporation filed an 8-K to announce its quarterly results for the first quarter ended March 31, 2024. The filing serves as a formal notice that financial results have been released via press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Report date: May 09, 2024.
- The filing includes the announcement of results of operations and financial condition under Item 2.02.
Tredegar Corporation entered into the Fourth Amendment to its Second Amended and Restated Credit Agreement, primarily extending timelines related to a planned asset sale. The amendment adjusts the ABL Adjustment Date and minimum EBITDA covenant levels to provide more time for the divestiture of its Terphane business.
🚩 Red Flags
- Mandatory weekly reporting requirement for Borrowing Base Certificates if liquidity drops below a 20% threshold.
- The company's maximum borrowing capacity is scheduled to decrease by $55 million upon the closing of the Terphane sale or by Sept 2025.
📋 Key Facts
- Entered into Amendment No. 4 to the Second Amended and Restated Credit Agreement on April 16, 2024.
- The 'ABL Adjustment Date' (the date maximum borrowing reduces from $180M to $125M) was extended from March 31, 2025, to September 30, 2025.
- Monthly minimum Consolidated EBITDA covenant levels were extended to September 2025.
- The company must provide weekly Borrowing Base Certificates if availability falls below 20% of the Aggregate Commitment.
- The ABL reduction is tied to the closing of the Terphane business sale or September 30, 2025.
Tredegar Corporation announced its financial results for the fourth quarter and full fiscal year ended December 31, 2023. The filing serves as a formal notification of the release of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: March 15, 2024
- Period covered: Fourth quarter and full year ended December 31, 2023
- The filing includes results of operations and financial condition under Item 2.02
- Information is furnished via Exhibit 99 (Press Release) rather than filed for liability purposes under Section 18